Neurocrine Biosciences (NBIX) -2.8% AH after announcing a Phase II study for its NBI-98854 drug...

|About: Neurocrine Biosciences, Inc. (NBIX)|By:, SA News Editor

Neurocrine Biosciences (NBIX) -2.8% AH after announcing a Phase II study for its NBI-98854 drug for treating tardive dyskinesia failed to meet its primary endpoint, when a site featuring "inconsistent and incorrect application" of its assessment protocol was included. Without the site in question, the study showed a significant reduction in TD symptoms.